Protagonist Therapeutics (PTGX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $128.75, -5.71% vs the prior close of $136.55.
- Volume 886.73K shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PTGX slides 5.7% to $128.75, a 3-month low. Closed at $128.75, -5.71% vs the prior close of $136.55. Day range $126.39–$136.55, opened at $136.16.
PTGX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PTGX slides 5.7% to $128.75, a 3-month low
- Closed at $128.75, -5.71% vs the prior close of $136.55. Day range $126.39–$136.55, opened at $136.16.
- Volume was 886.73K shares, 1.3x its 50-day average of 659.84K.
- Price is -11.4% vs its 50-day average ($145.39) and +13.2% vs its 200-day average ($113.77).
- 52-week range $73.08–$160.81; today's close sits at 63% of that range, 19.9% below the 52-week high.
Oct 15, 2026 — PTGX ends flat (+0.2%) to $136.55
- Closed at $136.55, +0.20% vs the prior close of $136.28. Day range $136.02–$139.11, opened at $136.72.
- Volume was 707.70K shares, 1.1x its 50-day average of 654.30K.
- Price is -6.3% vs its 50-day average ($145.74) and +20.2% vs its 200-day average ($113.56).
- 52-week range $73.08–$160.81; today's close sits at 72% of that range, 15.1% below the 52-week high.
Oct 14, 2026 — PTGX dips 1.6% to $136.28, a 1-month low
- Closed at $136.28, -1.60% vs the prior close of $138.49. Day range $135.62–$141.13, opened at $138.06.
- Volume was 679.00K shares, 1.0x its 50-day average of 653.41K.
- Price is -6.5% vs its 50-day average ($145.75) and +20.3% vs its 200-day average ($113.32).
- 52-week range $73.08–$160.81; today's close sits at 72% of that range, 15.3% below the 52-week high.
Oct 13, 2026 — PTGX slides 4.4% to $138.49
- Closed at $138.49, -4.41% vs the prior close of $144.88. Day range $137.81–$146.00, opened at $146.00.
- Volume was 1.03M shares, 1.6x its 50-day average of 641.80K.
- Price is -5.0% vs its 50-day average ($145.74) and +22.5% vs its 200-day average ($113.08).
- 52-week range $73.08–$160.81; today's close sits at 75% of that range, 13.9% below the 52-week high.
Oct 12, 2026 — PTGX rises 0.8% to $144.88
- Closed at $144.88, +0.80% vs the prior close of $143.73. Day range $143.69–$152.18, opened at $145.83.
- Volume was 898.50K shares, 1.4x its 50-day average of 634.80K.
- Price is -0.5% vs its 50-day average ($145.62) and +28.4% vs its 200-day average ($112.83).
- 52-week range $65.75–$160.81; today's close sits at 83% of that range, 9.9% below the 52-week high.
Oct 9, 2026 — PTGX rises 2.7% to $143.73
- Closed at $143.73, +2.73% vs the prior close of $139.91. Day range $138.95–$146.30, opened at $139.91.
- Volume was 762.20K shares, 1.2x its 50-day average of 630.69K.
- Price is -1.2% vs its 50-day average ($145.46) and +27.7% vs its 200-day average ($112.55).
- 52-week range $65.56–$160.81; today's close sits at 82% of that range, 10.6% below the 52-week high.
Oct 8, 2026 — PTGX dips 0.7% to $139.91
- Closed at $139.91, -0.72% vs the prior close of $140.92. Day range $137.99–$142.18, opened at $139.57.
- Volume was 1.00M shares, 1.6x its 50-day average of 621.90K.
- Price is -3.7% vs its 50-day average ($145.35) and +24.6% vs its 200-day average ($112.27).
- 52-week range $64.50–$160.81; today's close sits at 78% of that range, 13.0% below the 52-week high.
Oct 7, 2026 — PTGX rises 1.6% to $140.92
- Closed at $140.92, +1.61% vs the prior close of $138.69. Day range $137.25–$144.10, opened at $137.34.
- Volume was 927.30K shares, 1.5x its 50-day average of 609.00K.
- Price is -3.0% vs its 50-day average ($145.22) and +25.8% vs its 200-day average ($112.00).
- 52-week range $62.24–$160.81; today's close sits at 80% of that range, 12.4% below the 52-week high.
Oct 6, 2026 — PTGX dips 1.4% to $138.69
- Closed at $138.69, -1.38% vs the prior close of $140.63. Day range $136.09–$141.00, opened at $140.34.
- Volume was 635.70K shares, 1.1x its 50-day average of 604.62K.
- Price is -4.4% vs its 50-day average ($145.13) and +24.1% vs its 200-day average ($111.72).
- 52-week range $62.24–$160.81; today's close sits at 78% of that range, 13.8% below the 52-week high.
Oct 5, 2026 — PTGX rises 0.4% to $140.63 on 2.2x normal volume
- Closed at $140.63, +0.41% vs the prior close of $140.06. Day range $138.08–$142.51, opened at $139.96.
- Volume was 1.27M shares, 2.2x its 50-day average of 585.11K — unusually heavy trading.
- Price is -3.1% vs its 50-day average ($145.07) and +26.2% vs its 200-day average ($111.48).
- 52-week range $62.24–$160.81; today's close sits at 80% of that range, 12.5% below the 52-week high.
Oct 2, 2026 — PTGX rises 0.6% to $140.06
- Closed at $140.06, +0.63% vs the prior close of $139.19. Day range $138.37–$141.71, opened at $140.99.
- Volume was 760.30K shares, 1.3x its 50-day average of 582.02K.
- Price is -3.4% vs its 50-day average ($144.98) and +25.9% vs its 200-day average ($111.23).
- 52-week range $62.24–$160.81; today's close sits at 79% of that range, 12.9% below the 52-week high.
PTGX latest news & SEC filings
Every SEC filing by or about PTGX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ali Asif converted options/RSUs into 9,229 shares at $38.98 (≈$359.75K) on Sep 30, 2026; now holds 68,232
- Ali Asif converted options/RSUs into 28,438 shares at $23.42 (≈$666.02K) on Sep 30, 2026; now holds 96,670
- Ali Asif converted options/RSUs into 15,650 shares at $19.19 (≈$300.32K) on Sep 30, 2026; now holds 112,320
- Ali Asif converted options/RSUs into 5,312 shares at $12.17 (≈$64.65K) on Sep 30, 2026; now holds 117,632
- Ali Asif sold 12,595 shares at $141.77 (≈$1.79M) on Sep 30, 2026; now holds 105,037
- Ali Asif sold 46,034 shares at $141.78 (≈$6.53M) on Sep 30, 2026; now holds 59,003
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Patel Dinesh V Ph D sold 7,278 shares at $144.10 (≈$1.05M) on Sep 10, 2026
- Patel Dinesh V Ph D sold 7,278 shares at $144.10 (≈$1.05M) on Sep 10, 2026
- Patel Dinesh V Ph D sold 7,278 shares at $144.10 (≈$1.05M) on Sep 10, 2026
- Patel Dinesh V Ph D sold 7,278 shares at $144.10 (≈$1.05M) on Sep 10, 2026
- Patel Dinesh V Ph D sold 63,548 shares at $146.18 (≈$9.29M) on Sep 9, 2026
- Patel Dinesh V Ph D sold 63,548 shares at $146.18 (≈$9.29M) on Sep 9, 2026
- …plus 6 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Patel Dinesh V Ph D sold 34,239 shares at $148.52 (≈$5.09M) on Aug 11, 2026
- Patel Dinesh V Ph D sold 34,239 shares at $148.52 (≈$5.09M) on Aug 11, 2026
- Patel Dinesh V Ph D sold 34,239 shares at $148.52 (≈$5.09M) on Aug 11, 2026
- Patel Dinesh V Ph D sold 34,239 shares at $148.52 (≈$5.09M) on Aug 11, 2026
- Patel Dinesh V Ph D sold 65,761 shares at $149.11 (≈$9.81M) on Aug 10, 2026
- Patel Dinesh V Ph D sold 65,761 shares at $149.11 (≈$9.81M) on Aug 10, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Aug 5, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Aug 5, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Aug 5, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Aug 5, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Aug 5, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Aug 5, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Things to know before you trade PTGX
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 25, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.65% (largest 5.7%).
- Liquidity: about 830.52K shares (≈$106.93M) trade per day on average.
- 52-week position: $128.75 vs a range of $73.08–$160.81 (63% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Dinesh V Ph D Patel sold 7,278 shares on Sep 10, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 18, 2026.
- Share count: 64.71M shares outstanding (Jul 31, 2026), +4.0% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PTGX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 136.16 | 136.55 | 126.39 | 128.75 | 886.73K |
| Oct 15, 2026 | 136.72 | 139.11 | 136.02 | 136.55 | 707.70K |
| Oct 14, 2026 | 138.06 | 141.13 | 135.62 | 136.28 | 679.00K |
| Oct 13, 2026 | 146.00 | 146.00 | 137.81 | 138.49 | 1.03M |
| Oct 12, 2026 | 145.83 | 152.18 | 143.69 | 144.88 | 898.50K |
| Oct 9, 2026 | 139.91 | 146.30 | 138.95 | 143.73 | 762.20K |
| Oct 8, 2026 | 139.57 | 142.18 | 137.99 | 139.91 | 1.00M |
| Oct 7, 2026 | 137.34 | 144.10 | 137.25 | 140.92 | 927.30K |
| Oct 6, 2026 | 140.34 | 141.00 | 136.09 | 138.69 | 635.70K |
| Oct 5, 2026 | 139.96 | 142.51 | 138.08 | 140.63 | 1.27M |
| Oct 2, 2026 | 140.99 | 141.71 | 138.37 | 140.06 | 760.30K |
| Oct 1, 2026 | 139.23 | 143.68 | 138.37 | 139.19 | 886.20K |
| Sep 30, 2026 | 141.60 | 143.74 | 140.44 | 140.89 | 787.70K |
| Sep 29, 2026 | 143.45 | 144.09 | 138.88 | 140.97 | 508.00K |
| Sep 28, 2026 | 142.21 | 143.68 | 140.24 | 142.44 | 925.50K |
| Sep 25, 2026 | 141.81 | 143.45 | 138.23 | 141.86 | 809.20K |
| Sep 24, 2026 | 138.76 | 140.80 | 134.10 | 137.34 | 989.20K |
| Sep 23, 2026 | 144.27 | 145.28 | 137.88 | 138.70 | 513.20K |
| Sep 22, 2026 | 144.64 | 147.71 | 144.50 | 145.07 | 806.20K |
| Sep 21, 2026 | 143.22 | 145.37 | 141.09 | 144.98 | 822.20K |
About Protagonist Therapeutics
Protagonist Therapeutics (PTGX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEWARK, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1377121.
PTGX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Bryan Giraudo | Director | May 11, 2026 |
| Sarah A O'Dowd | Director | Jan 6, 2026 |
| Dinesh V Ph D Patel | President and CEO | Sep 10, 2026 |
| Harold E Selick | Director | Mar 27, 2026 |
| William D. Waddill | Director | Jun 25, 2026 |
| Lewis T Williams | Director | Feb 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Asif Ali | Chief Financial Officer | Apr 21, 2026 |
| Arturo Md Molina | Chief Medical Officer | Mar 27, 2026 |
| Dinesh V Ph D Patel | President and CEO | Sep 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 10, 2026 | Dinesh V Ph D Patel | Sale | 7,278 | $144.10 |
| Sep 10, 2026 | Dinesh V Ph D Patel | Sale | 7,278 | $144.10 |
| Sep 10, 2026 | Dinesh V Ph D Patel | Sale | 7,278 | $144.10 |
| Sep 10, 2026 | Dinesh V Ph D Patel | Sale | 7,278 | $144.10 |
| Sep 9, 2026 | Dinesh V Ph D Patel | Sale | 63,548 | $146.18 |
| Sep 9, 2026 | Dinesh V Ph D Patel | Sale | 63,548 | $146.18 |
| Sep 9, 2026 | Dinesh V Ph D Patel | Sale | 63,548 | $146.18 |
| Sep 9, 2026 | Dinesh V Ph D Patel | Sale | 63,548 | $146.18 |
| Sep 8, 2026 | Dinesh V Ph D Patel | Sale | 54,174 | $145.87 |
| Sep 8, 2026 | Dinesh V Ph D Patel | Sale | 54,174 | $145.87 |
| Sep 8, 2026 | Dinesh V Ph D Patel | Sale | 54,174 | $145.87 |
| Sep 8, 2026 | Dinesh V Ph D Patel | Sale | 54,174 | $145.87 |
| Aug 11, 2026 | Dinesh V Ph D Patel | Sale | 34,239 | $148.52 |
| Aug 11, 2026 | Dinesh V Ph D Patel | Sale | 34,239 | $148.52 |
| Aug 11, 2026 | Dinesh V Ph D Patel | Sale | 34,239 | $148.52 |
PTGX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-130.15M | -2.05 | $57.67M |
| Dec 31, 2024 | — | $275.19M | 4.23 | $184.15M |
| Dec 31, 2023 | — | $-78.95M | -1.39 | $-70.24M |
| Dec 31, 2022 | — | $-127.39M | -2.60 | $-108.14M |
| Dec 31, 2021 | — | $-125.55M | -2.71 | $-107.86M |
Latest balance sheet: total assets $885.54M, total liabilities $44.00M, cash $420.08M (as of Jun 30, 2026).
PTGX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $137.32 |
| May 5, 2026 | 8-K Item 2.02 (results) | $99.21 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $87.10 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $79.78 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $53.87 |
| May 6, 2025 | 8-K Item 2.02 (results) | $42.01 |
| Feb 21, 2025 | 8-K Item 2.02 (results) | $38.75 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $47.61 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PTGX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.